Rapid Medical Secures $20 Million Series C Funding to Advance Neurovascular Bypass Devices for Cardiovascular Disease Treatment

VCBeat (WeChat Official Account: vcbeat) learned from foreign media that on April 24, local time in Israel, medical device company Rapid Medical completed a $20 million Series C financing round. The funds from this round will be used to develop vascular bypass devices and improve the cure rate for cardiovascular diseases.

It is reported that this round of financing was led by JAM Capital Partners, with participation from RocSon Medtech Fund.

Rapid Medical, headquartered in northern Israel, is a medical device company specializing in the development of safe and effective neurovascular medical devices to meet market demand for the treatment of vascular diseases. The company’s current product portfolio includes Tigertriever, Tigertriever13, and Comaneci.

Tigertriever, developed by the company for the treatment of ischemic stroke, is a controllable and fully visible biological stent designed for patients. It is also the first controllable aneurysm neck bridging device in history. Vascular diseases are typically caused by narrowing of blood vessels, blockages, or ruptures. In previous treatment protocols, the bridging devices used during bypass surgery were generally uncontrollable; once implanted, they could not be monitored by external equipment, preventing medical teams from assessing the status of the bridging medium. This bridging device can connect to external medical equipment, allowing medical teams to monitor the status of the cardiac bypass device at any time after implantation. If collapse or rejection occurs, the medical team can promptly implement an alternative treatment plan to help the patient complete the procedure. Tigertriever13 is an upgraded version of Tigertriever, featuring optimized remote control mechanisms and other enhanced services.

Rapid Medical’s other flagship product, Comaneci, is an arterial debris clearance device. The continuous flow of blood in the vessels enables the body to digest and absorb various substances; for instance, red blood cells transport oxygen throughout the body. Once an artery becomes blocked, the lack of essential nutrients or the inability to clear metabolic toxins can lead to severe consequences, such as stroke, cerebral infarction, or even brain death. Traditional vascular clearance procedures often trigger immune rejection responses between medical devices and the human body, impairing arterial function and potentially causing vascular damage that results in numerous long-term complications. Leveraging biological principles, Comaneci adsorbs impurities from the arteries without inducing rejection reactions, removing them from the body to help soften vessel walls and restore unobstructed blood flow. Currently, this product is primarily marketed in Europe.

Ronen Eckhouse, CEO and Co-Founder of Rapid Medical, stated, “We are grateful for the support from our new round of investors. Bridging procedures are widely used in the medical field, but they often encounter problems due to limitations in medical devices. We hope to provide patients with the best possible care through our medical devices.”

JAM Capital Partners, established in 2010, is a private investment partnership firm primarily focused on early-stage enterprise development.

RocSon Medtech Fund is an investment fund headquartered in the Cayman Islands, primarily investing in startups in the medical sector, and has completed two investments to date.

(Compiled by Liu Yujing)